# A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

> **NCT02824055** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 33 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO5545965

## Key facts

- **NCT ID:** NCT02824055
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-27
- **Primary completion:** 2017-04-24
- **Final completion:** 2017-04-24
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824055, "A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02824055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*